News Lilly’s Taltz scrapes win against Humira in psoriatic arthri... Eli Lilly’s Taltz has beaten AbbVie’s blockbuster Humira in a psoriatic arthritis study involving patients who hadn’t been treated before with a disease-modifying drug, but only just.
News Amid tough competition, Novartis makes case for rheumatology... Swiss pharma hopes to bounce back from Q1 sales disappointment
News Novartis tests Cosentyx against Humira and biosimilars Trials will cover psoriatic arthritis and ankylosing spondylitis
News Pfizer's Xeljanz approved in psoriatic arthritis Xeljanz is first JAK inhibitor approved in psoriatic arthritis
News Novartis weathers Entresto slump with return to growth Novartis saw sales grow 3% in the second quarter, returning to growth after a 1% fall in the first quarter caused by generic competition to Entresto.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
